Zhejiang Jiuzhou Pharmaceutical603456.SHValuation Analysis

As of Oct 19, 2026, Zhejiang Jiuzhou Pharmaceutical (603456.SH) trades at a P/E of 24.00x, P/B of 1.60x, P/S of 2.75x, and a dividend yield of 1.86%.
Longitudinal percentile comparison: P/E sits at the 30th percentile over the trailing 10Y window (vs. 86th percentile over 3Y); P/B sits at the 15th percentile over the trailing 10Y window (vs. 48th percentile over 3Y); P/S sits at the 19th percentile over the trailing 10Y window (vs. 58th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 30th percentile within its industry and the 33rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.58%, ranking at the 83rd percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 14.8 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 2.58% total shareholder yield, 1.86% is paid out as dividends and roughly 0.72% is implied to come from buybacks — both channels are meaningfully in play. Zhejiang Jiuzhou Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.